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Abstract
Human immunodeficiency virus (HIV) genetic compartmentalization is defined as genetic differences in HIV in different tissue
compartments or subcompartments that characterize viral quasispecies. This descriptive, longitudinal study assessed the dynam-
ics of inflammation, humoral immune response, blood-brain barrier, blood-cerebrospinal fluid (CSF) barrier, as well as neuronal
injury biomarkers in serially obtained CSF and serum samples from an antiretroviral (ARV) therapy-naïve patient with HIV-1
subtype C with CSF HIV genetic compartmentalization that resolved spontaneously without ARV treatment. The first CSF
sample showed an increase in white blood cell (WBC) count (382 cells/mm3) and a marked increase in the levels of inflammatory
cytokines and chemokines, including tumor necrosis factor (TNF)α, interleukin (IL)-10, IP-10, and regulated on activation,
normal T cell expressed and secreted (RANTES), which raise the suspicion of dual infection. Serum sample analysis showed all
cytokine levels to be normal, with only IP-10 slightly increased. These results corroborate the hypothesis that the CNS immu-
nologic response in a patient with HIV infection was independent of the systemic immunologic response. The patient also had
persistently elevated levels of sCD14, neopterin, and β2M, which were strongly suggestive of persistent CNS immunologic
stimulation. This report describes a patient with HIV subtype C who developed a transient episode of asymptomatic HIV
meningitis with compartmentalization of HIV in the CSF that resolved independently of ARV therapy. Extensive CSF studies
were performed as part of an ongoing longitudinal study, which revealed CNS immune abnormalities. This case presents
evidence of HIV-1 subtype C neurotropism and compartmentalization.
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Introduction
HIV-1 infects the central nervous system (CNS) almost imme-
diately after transmission and causes HIV-associated neurode-
generation (Spudich et al. 2011; Valcour et al. 2012). Previous
studies have reported a subset of individuals presenting with
cerebrospinal fluid (CSF) viral escape, regardless of sustained
HIV suppression in the blood during antiretroviral (ARV)
therapy (Lescure et al. 2013; Canestri et al. 2010). The discor-
dance between HIV viral loads in the CSF and plasma is
defined according to the detectable HIV RNA levels in the
CSF, i.e., the viral load in the plasma is < 50 copies/mL and in
the CSF is > 200 copies/mL or the HIV RNAviral load in the
CSF is ≥ 1 log higher than that in the plasma (Canestri et al.
2010). Moreover, CNS HIV compartmentalization, presumed
to be a late-stage event associated with prolonged HIV infec-
tion or HIV encephalitis, may be a dynamic event that can
occur in the earliest stage of HIV infection (Schnell et al.
2010; Sturdevant et al. 2012, 2015).
Previous studies have performed extensive characterization
of HIV-1 subtype B CNS infection. However, little is known
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about the dynamics of CNS infection of HIV-1 subtype C,
which is the most prevalent subtype worldwide. Hence, this
study aimed to evaluate the dynamics of several biomarkers
related to inflammation, neuronal injury, immunoglobulin G
(IgG) intrathecal synthesis, blood-brain barrier (BBB), and
blood-CSF barrier (BCSFB) in serial CSF and serum samples
from an asymptomatic individual from Southern Brazil who
was infected with HIV-1 subtype C. To our knowledge, this
was the first report of asymptomatic disagreement between
HIV viral loads in CSF and plasma (CSF > plasma) that re-
solved spontaneously without ARV treatment.
Methods
This study was approved by the institutional review board
(IRB) of Hospital de Clínicas–Universidade Federal do
Paraná (UFPR) and the National IRB (CONEP) in Brazil.
Specimen collection and storage: HIV-positive CSF
and serum samples
We evaluated CSF and blood samples sequentially collected
from a 51-year-old heterosexual Caucasian man with 13 years
of education who was employed as a motorcycle courier. The
participant was tested for HIV because his wife had been
diagnosed with AIDS and CNS toxoplasmosis in October
2008 (the wife’s nadir CD4 was 45 cells/mm3). She was a
housewife and was infected by heterosexual transmission.
The participant provided four longitudinal paired CSF and
blood samples: (A) March 27, 2009, not on ARV, in which
discordance in CSF and blood HIV RNA levels was identi-
fied; (B) November 29, 2013; (C) August 29, 2014, 6 months
after starting ARV therapy; and (D) September 23, 2016. All
CSF samples were collected by lumbar puncture in polypro-
pylene tubes to avoid proteins adherence to the tube walls and
were stored at − 80 °C, in HC-UFPR, Brazil.
HIV-negative control group (n = 19)
Although this was a descriptive study, we compared the levels
of biomarkers found in this case report to those in an HIV-
negative control group because the normal ranges of most of
the biomarkers in this study were not defined. The HIV(−)
group was described previously (de Almeida et al. 2016a, b).
Clinical laboratory parameters
CSF biochemistry and cytology were quantified by standard
methods. The HIV RNA in the serum and CSF were quanti-
fied using a branched DNA assay (Siemens) with a nominal
limit of detection of 50 copies/mL.
Sequence filtering, dual infection (DI) screening,
and bioinformatics analysis
We amplified the HIV-1 env C2-V3 (HXB2 coordinates
6928–7344) region from RNA extracted from the CSF and
HIV DNA from peripheral blood mononuclear cells
(PBMC) by nested polymerase chain reaction (PCR) using
specific primers. Sequencing was performed using an NGS
454 GS FLX Titanium system (454 Life Sciences, Roche,
Branford, Connecticut, USA). Read (FASTA) and quality
score files produced by the 454 instruments were further ana-
lyzed using a purpose-built bioinformatics pipeline used by
our group in numerous published studies (Fisher et al. 2015;
Carter et al. 2015; Wagner et al. 2014). The pipeline is avail-
ab l e a t h t tps : / / g i thub .com/veg /HIV-NGS . Vi ra l
compartmentalization was assessed by the F-statistics (Fst)
(p < 0.01) (Hudson et al. 1992), which was used to measure
the genetic distance between populations (Chen and Wang
2015). The statistical significance was derived via 1000
population-structure randomization/permutation test. Viral
compartmentalization analysis via Fst statistics was repeated
using representative haplotypes to guard against the possible
skewing of allelic frequencies due to PCR amplification.
Evidence of dual infection (DI) in gag and/or env was ex-
plored as previously described (Wagner et al. 2014, 2016).
Briefly, representative haplotypes from the CSF, PBMC, and
blood plasma for each coding region were assembled into
separate phylogenies with (i) all GenBank HIV-1 subtype C
sequences from Brazil and (ii) representative haplotypes from
Curitiba’s local cohort from Brazil. Evidence of intermingled
sequences between input haplotypes and background se-
quences suggested potential DI that could have been missed
by focusing on intrasample diversity while well-segregated
sequences argued against potential DI.
CSF and serum soluble biomarkers
All samples were assayed concurrently in duplicate according to
the manufacturers’ instructions. We evaluated the levels of sev-
eral soluble biomarkers in CSF and serum: Inflammation
biomarkers, including tumor necrosis factor α (TNFα), interfer-
on γ (IFNγ), interleukins (IL-1β, IL-2, IL-4, IL-6, IL-7, and IL-
10), monocyte chemoattractant protein-1 (MCP-1), macrophage
inflammatory protein-1α and β (MIP-1α and β), interferon
gamma-induced protein-10 (IP-10), were quantified bymultiplex
bead suspension array immunoassays (EMDMillipore, Billerica,
MA). Regulated during activation, normal T cell expressed and
secreted (RANTES) and urokinase plasminogen activator recep-
tors (uPARs) were quantified by high-sensitivity enzyme-linked
immunosorbent assay (ELISA, R&D Systems, Minneapolis,
MN). We also measured levels of BBB markers, including sE-
Selectin, soluble cell adhesion molecules-1 (sVCAM-1), soluble
intercellular adhesion molecule-1, and metalloproteinase-2,
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metalloproteinase-3, and metalloproteinase-9 (MMP-2, MMP-3,
and MMP-9) using multiplex bead suspension array immunoas-
says (EMD Millipore, Billerica, MA). The tissue inhibitor
metalloproteinase-1 and tissue inhibitor metalloproteinase-2
( T IM P - 1 a n d T IM P - 2 ) w e r e m e a s u r e d b y
electrochemiluminescence assay (Meso Scale Discovery,
Rockville, MD). The levels of neuronal injury markers, includ-
ing phosphorylated tau-181 (pT-181, Thermo Fisher Scientific
Inc., Waltham, MA, USA), were assayed by multiplex bead
assays (FlexMAP 3D®, Luminex Corporation, Austin, TX,
USA); total tau, amyloid β (Aβ 38, 40, and 42), and soluble
amyloid precursor protein α and β (sAPPα and sAPPβ) were
measured using electrochemiluminescence assay (Meso Scale
Discovery, Rockville, MD). Neurofilament light (NFL-light)
was quantified using high-sensitivity ELISA (Uman
Diagnostic). Monocyte and macrophage activation: human β2
microglobulin (β2M) was quantified using the nephelometric
method (Dade Behring BNII, Deerfield, IL) with N latex β2
microglobulin (Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany). sCD-14 (R&D Systems,
Minneapolis, MN) and neopterin (Thermo Fisher Scientific)
were quantified by high-sensitivity ELISA. Microglia injury:
ferritin (Architect, Abbott, Longford, Ireland). Demyelization:
myelin basic protein (MBP, Ansh Labs) was quantified by
high-sensitivity ELISA. BCSFB function: CSF and serum albu-
min were quantified using the nephelometric method (Dade
Behring BNII, Deerfield, IL) with antiserum N human albumin
(Siemens Healthcare Diagnostics Products GmbH, Marburg,
Germany) and VR 7.0–34 mg/dL (Breebaart et al. 1978). The
functional integrity of the BCSFB was then assessed by calcu-
lating the CSF albumin/serum albumin quotient, QAlb =AlbCSF/
Albserum. The upper limit of the reference range was age-
dependent and was calculated for each sample using the follow-
ing equation: QAlb ref. = (4 + age [y]/15) × 10
−3 (Reiber and
Peter 2001). IgG intrathecal synthesis was assayed using quanti-
tative and qualitative methods. IgG in the CSF and serum were
quantified using the nephelometric method (Dade Behring BNII,
Deerfield, IL) with antiserumN human IgG (SiemensHealthcare
Diagnostics Products GmbH, Marburg, Germany) (Reiber et al.
2003). For the qualitative analysis of IgG intrathecal synthesis,
the CSF and serum samples were assayed to detect oligoclonal
bands by agarose gel isofocusing followed by IgG
immunofixation (Hydragel CSF Isofocusing-Sebia, Norcross,
GA). Quantitative analysis of IgG intrathecal synthesis and
BCSFB function was analyzed by IgG hyperbolic function and
Reibergram plot (Reiber 1995). The plots were generated using
CSF Research software.
Results
This was a descriptive, longitudinal study of the dynamics of
inflammation, humoral immune responses, BBB, and
BCSFB, as well as neuronal injury biomarkers in serially ob-
tained CSF and blood samples.
Patient clinical and laboratory parameters
The CSF cell and biochemistry measurements and clinical
characteristics over time are shown in Table 1. At the time
of the first CSF sample (A), the participant was classified
as non-AIDS, with an initial CD4 count of 692 cells/mm3
(March 27, 2009) and negative for hepatitis B and C virus
(HBV and HCV). He was asymptomatic, had no neuro-
logical complaints, had normal findings on neurological
and neuropsychological evaluation, and was categorized
as independent according to the Lawton Instrumental
Activities of Daily Living scale. HIV-1 genotyping indi-
cated subtype C. CSF samples were collected because the
patient voluntarily agreed to participate in an HIV
neurocognitive study. At time point A, the patient showed
lymphocytic meningitis with a severe increase in CSF
WBC (382 cells/mm3), but with normal lactate and glu-
cose levels (Table 1). Standard microbiological methods
were used to test for the presence of various infectious
etiologic agents, including virus, bacteria, and fungus,
but the results were negative and the patient’s CSF had
negative Venereal Disease Research Laboratory (VDRL)
test results. He was diagnosed with chronic HIV
meningitis.
Five years later (February 19, 2014), the patient was
categorized as A-2 based on the 1993 revised CDC classi-
fication system. ARV therapy was started with lamivudine
(3TC), tenofovir (TDF), and lopinavir/ritonavir (LPV/r):
Antiretroviral CNS penetration-effectiveness (CPE 2010)
(2 + 1 + 3 + 1) = 7; after 2 months, LPV/r was substituted
for efavirenz (EFZ) due to diarrhea in the ARV regimen:
CPE 2010 (2 + 1 + 3) = 6. The patient demonstrated good
treatment adherence and was responsive to ARV therapy.
The HIV RNA was suppressed in both CSF and blood
samples (Table 1).
Computed axial tomography (CAT) of the brain (12/07/
2016) showed a discrete prominence of basal cisterns,
brain, and cerebellar sulci. There was no pathological en-
hancement of the meninges after the administration of
intravenous iodinated contrast injection. A brain CAT
was not performed at the time of the first CSF sample
collection.
Phylogenetic analyses of CNS compartmentalization
and DI
We observed discordance in HIV RNA between the CSF
and plasma samples (CSF > plasma) at time point A in
which the viral load in the CSF sample was 2.6-log great-
er than that in the blood sample (Table 1). We amplified
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partial env and gag genes from the CSF and blood sam-
ples. The tree topology revealed evidence of compartmen-
talization in both env and gag regions between the blood
(plasma or PBMC) and CSF, which were confirmed using
the Fst approach (p < 0.01) (Hudson et al. 1992), but not
(though nearly significant) between the plasma and
PBMC (available for the gag region only) (Fig. 1).
The CSF and plasma HIV RNA disagreement disap-
peared spontaneously 56 months after HIV diagnosis
without ARV treatment (sample B); the HIV RNA were
higher in the blood than those in the CSF and the WBC
count and total protein levels in the CSF had decreased. It
was not possible to amplify HIV RNA in CSF sample B,
and HIV RNA was not detected in CSF samples C and D
(Table 1).
We evaluated the potential for DI in the gag and/or env
sequences from sample A by applying multiple approaches
with GenBank and local cohort HIV-1 subtype C sequences
for CSF, PBMC, and plasma. The results showed evidence of
mono-infection. Although this conclusion is limited by the
short region and single time point, we cannot reject the possi-
bility of a DI (Fig. 2a–c).
Dynamics of CSF and serum biomarkers
Monocyte and macrophage activation biomarkers
The CSF and serum values of the biomarkers of monocyte and
macrophage activation are shown in Table 2. sCD14 levels in
the CSF significantly were increased in time point A (6.5-fold
higher compared to the median values in the control group)
and decreased in sample C but was still higher than the median
values in the control group. The CSF neopterin levels were
increased in sample A (17-fold). It progressively decreased
but persisted higher than the control group in sample C. The
CSF Β2 microglobulin levels were increased in sample A (5-
fold), while those in sample B were increased 3-fold. The
increase in the levels of monocyte and macrophage activation
biomarkers was more severe in the CSF than that in the serum
(Table 2).
Table 1 Overtime clinical and
CSF cell and biochemistry
characteristics
A B C on ARV D on ARV
Date March 27, 2009 November 29, 2013 August 29, 2014 September 23, 2016
Time after HIV
diagnosis (months)
4 60 69 94
CDC classification2 A1 A1 A2 A2
IHDS 12 – 12 –
GDS 0.32 – – –
WBC (cell/mm3) 3821 33 28 1.2
Lymphocytes (%) 97 95 96 –
Mono (%) 03 05 04 –
RBC (cell/mm3) 84 0 1 12
Glucose (mg/dL) 44 54 52 66
TP (mg/dL) 91 51 47 39
Lactate (mmol/L) 1.7 1.4 1.7 –
CSF HIV VL (copies/mL) 135,868 35,177 ND ND
CSF HIV Log 5.13 4.55 – –
Blood HIV VL 5706 126,488 < 40 ND
Blood HIV log (copies/mL) 3.76 5.10 1.60 –
CSF IgG (mg/L) 302 192 1283 863
CSFAlb (mg/L) 501 188 211 191
Serum IgG (mg/L) 24,200 20,500 24,719 12,495
Serum Alb (mg/L) 30,600 22,400 32,000 37,000
Q IgG 0.013 0.009 0.0053 0.0073
Q Alb4 0.016 0.008 0.007 0.005
IgG index5 0.762 1.116 0.7853 1.3333
Blood CD46 (cell/mm3) 692 502 417 381
Blood CD86 (cell/mm3) 2376 2857 1677 1049
Blood CD4/CD86 0.29 0.18 0.25 0.36
ND not detectable, IHDS International HIV Dementia Scale (Sacktor et al. 2005), GDS global deficit score
1 CSF sample A; the investigation of other etiologies of increased CSF WBC was negative by standard microbi-
ological methods. CSF VDRL was negative in all samples
2 CDC revised classification for HIV infection, 1993 (CDC 1993)
3 CSF IgG estimated
4QAlb upper limits of the reference range, for samples A to D, were 7.4, 7.7, 7.8, and 7.9 respectively
5 IgG index = (IgG CSF/Alb CSF)/(IgG serum/Alb serum); reference value < 0.8
6 Current CD4 or CD8
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CSF and serum neuronal injury biomarkers
The NFL level was increased in all three CSF samples, al-
though with a trend toward normalization (Table 2). The
Aβ-40 levels also increased, while the Aβ-38 and Aβ-42
levels in the CSF sample A remained normal. All Aβ isoforms
were normal in sample C. The level of myelin basic protein
(MPB) was slightly increased, and the results were similar in
all three samples (Table 2).
Humoral immune response (IgG intrathecal synthesis)
The dynamics of intrathecal IgG synthesis and BCSFB dys-
function are shown in Fig. 3. CSF sample A showed
oligoclonal bands restricted to CSF, type 2 (Andersson et al.
1994). Oligoclonal bands were not analyzed in sequential
samples.
Cellular immune response (cytokines and chemokines)
The levels of CSF and serum cytokine and chemokine bio-
markers in the sample with CNS HIV compartmentalization
(sample A) compared to those in the HIV-negative control
group are shown in Table 3. In sample A, the levels of all
cytokines and chemokines quantified in the CSF, chiefly
TNFα, IL-10, IFNy, IP-10, and RANTES were elevated. In
the serum, the levels of all cytokines quantified were lower
than those in the control group, except for IL-10. The IP-10
levels were increased while the levels of other chemokines
remained normal. Analysis of the Th1/Th2 ratios revealed a
predominance of antiinflammatory cytokines (Th2 response)
Fig. 1 Approximate maximum likelihood phylogenetic reconstruction of
sequences generated from paired blood plasma and cerebrospinal fluid
(CSF) HIV-1 RNA and peripheral blood mononuclear cells (PBMC) HIV
DNA samples. HIV DNA and RNA haplotypes above a minimum
frequency threshold of 0.01 were extracted from reads covering the env
(a) and gag (b) regions for individual B0019 and were used to construct
approximate maximum likelihood phylogenies using FastTree (Price
et al. 2009). HIV DNA and RNA haplotypes are depicted in circles
with sizes indicative of the haplotype frequencies. Colors denote the
compartment of origin with blood plasma, CSF, and PBMC in red,
blue, and green respectively. Scale bars are in substitutions/site. This
analysis includes the sample collected when the HIV CSF escape was
identified (sample A). There was evidence of compartmentalization in
both the env and gag regions between the blood (plasma or PBMC) and
CSF, as confirmed using the Fst approach (Hudson et al. 1992) (p = 0.01
and 0.009 respectively), but not (though nearly significant, p = 0.06)
between plasma and PBMC, which was available for gag only. The
phylogenetic distance is shown at the bottom of each tree for reference.
a Paired blood plasma and CSF samples, partial env region. b Paired
blood plasma, PBMC, and CSF samples, partial gag region (color
figure online)
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in both the CSF and the serum. The CSF and serum values and
the magnitude of the increase compared with those of the
control group are shown in Table 3.
Blood-brain barrier biomarkers
In sample A, the sVCAM-1 and uPAR levels in the CSF were
higher than those in the control group and the levels of MMP-
9 (800-fold higher than the level in the control group) and its
respective tissue inhibitor TIMP-1 was also increased. There
was also an increase in the ratios of MMP-9/ TIMP-1 and
MMP-2/TIMP-2. In the serum, a slight increase in sVCAM-
1 and uPAR levels was observed. The ratios of MMP-9/
TIMP-1 and MMP-2/TIMP-2 in the serum were normal. The
levels of BBB biomarkers in the CSF and serum in the patient
with CNS HIV compartmentalization (sample A) were com-
pared to those in the HIV-negative control group (Table 3).
Discussion
We present a case of a patient infected with HIV-1 subtype C
who was non-AIDS, ARV naïve, and with asymptomatic HIV
meningitis. He showed discordance in the HIV RNA of CSF
and plasma, which resolved spontaneously and independent
of ARV therapy. This case presents evidence of HIV-1 subtype
C neurotropism and CNS compartmentalization. Different
from previous reports on HIV-1 subtypes B or C CNS com-
partmentalization (Canestri et al. 2010; van Lelyveld et al.
2010; Katlama et al. 2010; Bogoch et al. 2011; Bingham
et al. 2011; Tamarit M del et al. 2012; Peluso et al. 2014; de
0.04
0.03
0.03
0.02
0.04
0.02
a b c
Fig. 2 Dual infection (DI) screening. a Approximate maximum
likelihood phylogenies of CSF partial env and gag regions from our
sampled patient (blue) and all representative CSF haplotypes from
Curitiba’s local cohort from Brazil (black). b Phylogenies of blood
partial env and gag regions from our sampled patient (red) and all
representative blood haplotypes from Curitiba’s local cohort from Brazil
(black). c Phylogenies of blood partial env and gag regions from our
sampled patient (red) and GenBank HIV-1 subtype C sequences from
Brazil (black). All phylogenies are suggestive of mono-infection, but
the analyses are limited by the short region analyzed (partial env and
gag) and the lack of longitudinal sampling; therefore, we cannot reject
the potential for DI. The scale bar at the bottom represents the phyloge-
netic distance (substitutions/site). All phylogenies are rooted to
HXB2 (color figure online)
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Table 2 Dynamic of monocyte and macrophage activation and neuronal injury biomarkers on cerebrospinal fluid and serum of HIV-positive
participant compared with HIV negative control group
CSF Serum
Biomarker Unity A B C CTRL1 A B C CTRL1
Monocyte and macrophage activation biomarkers
sCD14 pg/mL 554,604 21,937 208,566 85,250 (69,540; 100,000) 2,109,465 2,163,727 747,710 1,437,000 (1,355,000; 1,549,000)
Neopterin nmol/L 85.96 26.07 14.11 4.99 (4.62; 5.64) – – – –
β2M
2 mg/L 6.08 4.30 – 1.3 ± 0.5 3.83 5.13 – 0.9–3.0
Ferritin3 ng/mL 8.76 5.95 4.90 5.00 (3.00; 7.00) 341 308 284 12–300
Neuronal injury biomarkers
T Tau pg/mL 492 197 21.10 634 (531.2; 764.6) – – – –
pTau 181 pg/mL 77.67 195 154 132.0 (106.5; 179.5) – – – –
Aβ-38 pg/mL 2439 2889 2507 2209 (1840; 2509) 2.48 2.48 2.48 7.23 (2.48; 22.50)
Aβ-40 pg/mL 5625 5379 4452 4561 (4182; 5116) 55.20 64.50 95.20 117.9 (108.0; 141.7)
Aβ-42 pg/mL 626 518 424 618 (549; 735) 2.72 4.26 7.94 7.98 (5.24; 9.55)
Aβ Total pg/mL 8690 8786 7383 7357 (6665; 8316) 71.25 105.62 140.6 (121.7; 172.6)
sAPPα ng/mL 19.20 – – 27.80 (16.40; 35.15) 27.51 – – 23.21 (17.99; 30.67)
sAPPβ ng/mL 22.00 – – 35.75 (27.05; 43.35) 1.68 – – 2.57 (1.78; 4.72)
sAPPα/β 0.87 – – 0.76 (0.60; 0.87) 16.36 – – 8.68 (4.78; 13.26)
NFL pg/mL 1428 966 744 660 (539; 802) – – – –
MBP4 ng/mL 1.42 1.13 1.33 < 1.10 – – – –
1Median (IQR)
2β2M normal range (Caudie et al. 2005)
3 Ferritin normal range (Petzold et al. 2002)
4Myelin basic protein (MBP) normal range (Greene et al. 2012)
Fig. 3 Hyperbolic function (Reibergram plot) of blood-CSF barrier
function and intrathecal IgG synthesis. The graph shows the dynamics
of intrathecal IgG synthesis and blood-CSF barrier (BCSFB) dysfunction.
Hyperbolic functions are a consequence of nonlinear interactions of
molecular flux with the CSF flow rate, as derived from the laws of
diffusion (Reiber 1995). BCSFB dysfunction is indicated on the graph
in the area with vertical stripes; the age-corrected normal range for QAlb
was 6 × 10−3. The plot was generated using CSF research software.
Sample A was col lected at the t ime when the CNS HIV
compartmentalization was identified, before antiretroviral (ARV)
initiation, showing BCSFB dysfunction; sample B was collected
56 months after the CNS HIV compartmentalization diagnosis, still
without ARV, showing decrease of BCSFB dysfunction and 30% IgG
intrathecal synthesis, in addition to CSF WBC and total protein
improvement. The IgG values were estimated (open circle) in samples
C and D; no BCSFB dysfunction was noted in these samples, but IgG
intrathecal synthesis persisted despite the initiation of ARV (sample C)
and normal CSF WBC values (sample D)
J. Neurovirol.
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Almeida et al. 2017), the present case did not meet the report-
ed risk factors, such as low CD4+ T cell nadir and advanced
immunosuppression, presence of HIV-associated dementia
(HAD), and poor adherence to ART (Ritola et al. 2005;
Harrington et al. 2009; Canestri et al. 2010; Schnell et al.
2010; Peluso et al. 2014).
The overall biomarker analysis showed that (1) concurrent
with the increase in CSF WBC count (viral meningitis), the
levels of most CSF neuroinflammation biomarkers, including
all ß-chemokines, also increased. (2) This finding showed that
ß-chemokines were successfully stimulated by HIV-1 subtype
C, contrary to previous reports (Satishchandra et al. 2000;
Ranga et al. 2004). (3) A severe increase in CSF biomarker
levels in contrast with the patient’s asymptomatic presenta-
tion, including normal cognitive function. (4) Concurrent with
HIV-1 subtype C CNS compartmentalization, there was a
marked increase in the CSF WBC count and levels of CSF
inflammatory, microglia, and neuronal injury biomarkers in-
cluding NFL, with a slight impact on β-amyloid metabolism
and no demyelination. (6) Persistent monocyte and macro-
phage activation and IgG intrathecal synthesis lasting more
than 5 years were consistent with the persistence of CNS im-
munological stimulation, as HIV persisted in a latent state in
microglia and astrocytes despite a controlled CSF HIV viral
load. (7) The cellular immune response to HIV in the CSFwas
different from that in the serum. The response was stronger in
the CNS than that in the peripheral blood, indicating that the
CNS cellular immune response was compartmentalized (de
Almeida et al. 2016a). (8) The levels of several biomarkers
were higher in the CSF than those in the serum, strongly
indicating intrathecal production. (9) The CSF HIV compart-
mentalization was accompanied by BCSFB dysfunction and
BBB disruption with increased levels of cell adhesion mole-
cules and metalloproteinases.
CNS escape has been described in association with and
without symptoms. It was reported asymptomatic CSF escape
in about 10% of a group of ART-treated patients with sup-
pressed systemic HIV replication. The increased CSF HIV
viral load (VL) was associated with intrathecal immune acti-
vation and appeared to be clinically benign (Eden et al. 2010;
Ferretti et al. 2015). Although different from the present case,
CSF pleocytosis was not observed in the previous cases.
The increases WBC count with lymphocyte and inflamma-
tory biomarkers in sample A could be interpreted as HIV
chronic meningitis exacerbated by HIV CNS compartmental-
ization. However, no other aspects in the patient’s history
could have triggered meningitis. The severe increase in
WBC count is not common in HIV chronic meningitis; how-
ever, the concomitant increase in all CSF cytokines and
chemokines resembled acute HIV meningitis (Marshall et al.
1988). Although the patient had been diagnosed with HIV
infection 4 months earlier, the duration of infection could have
been longer due to the occurrence of his wife’s AIDS. This
raises the possibility of dual infection (DI); however, specific
phylogenetic analysis revealed mono-infection. In addition,
the HIV viral load in the blood was consistent with chronic
infection, arguing against the DI hypothesis.
DI results in the presence of two variants, each originating
from an independent infection event. When the second infec-
tion occurs after seroconversion, it is called DI; when the
second infection occurs nearly simultaneously with the first,
or at least before seroconversion, the condition is generally
considered co-infection (Waters and Smit 2012). The overall
frequency of HIV DI varies between 0 and 20% (Hebberecht
et al. 2018). However, the number of well-documented DI
reports remains low, possibly because of difficulties in dem-
onstrating this condition (Hebberecht et al. 2018).
HIV chronic meningitis occurs in 13 to 40% of HIV-
positive individuals at any stage of infection (Marshall et al.
1988; Hollander et al. 1994) and approximately 59% are
asymptomatic. The WBC count is less than that measured in
the present case, with a median (IQR) count of 10 (8; 22) cells/
mm3 (de Almeida et al. 2011). This is an exclusion diagnosis
in which any other causes of chronic meningitis by opportu-
nistic or co-infection must be ruled out (Marshall et al. 1988;
Hollander et al. 1994).
The results of this study support the findings of a previous
study from the same group, showing that HIV-1 subtype C is
as neurotropic as subtype B and also able to develop CNS
HIV genetic compartmentalization (de Almeida et al. 2017).
Moreover, previous studies found similar frequencies of HIV-
C and B neurological and psychiatric manifestations as well as
similar stimulation of ß-chemokines and inflammatory bio-
markers in the CSF (de Almeida et al. 2013, 2016a, b).
These findings are contrary to a previous report that HIV-1
subtype C was less neuropathogenic than subtype B
(Satishchandra et al. 2000).
These results should be interpreted with caution and should
not be generalized to other HIV patients or groups. This study
had several limitations. First, this was a descriptive study with
a limited number of samples. There was no evidence of DI,
but this observation was limited to a short sequence region and
a single time point, which limited the possibility to reject the
potential for DI. In addition, the phylogenic analysis could
only be done for the first sample. In the following CSF sam-
ples, it was not possible to amplify HIV RNA or complemen-
tary DNA, making it difficult to determine the possibility of
transient CNS HIV genetic compartmentalization. The loss of
amplification might reflect a low HIV RNA copy number in
the CSF, while the compartmentalization may still be present.
However, the HIV viral load in the second CSF sample was
lower than that of the plasma and there was a decrease in
WBC count, suggesting that the HIV compartmentalization
was resolved.
Despite the limitations of this study, we showed that inde-
pendent and isolated HIV replication can occur in the CNS of
J. Neurovirol.
patients infected with HIV-1 subtype C, which can lead to
compartmentalization and development of quasispecies dis-
tinct from the peripheral plasma that are associatedwith strong
cell and humoral immunological responses, BBB dysfunction,
and brain injury.
From a pathophysiological standpoint, it is difficult to deter-
mine the clinical consequences of these episodes. Additional
studies are necessary to establish if these events could lead to
an increased risk of HAD or if they represent the natural history
of HIV infection in CNS without clinical consequences.
Previously reported cases of asymptomatic increases in CSF
HIVVL reported no neurological progression (Eden et al. 2010).
These findings provide evidence for the future develop-
ment of hypotheses and further investigation of CSF compart-
mentalization in asymptomatic HIV participants and provide
support for HIV-1 subtype C neurotropism and neurovirulence
studies. Future studies with larger sample sizes with adequate
statistical analysis are necessary to validate these results.
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